The short answer: no. There is no retatrutide pill, approved or in any registered trial.
Every retatrutide study on ClinicalTrials.gov gives it as an injection under the skin. Lilly hasn't announced an oral version. If you've seen "retatrutide capsules" for sale, nobody has tested that product in a trial, and nobody can tell you what's in it.
There are two approved GLP-1 pills for weight loss in the US, though. They're worth understanding, because they show exactly why a peptide pill is hard to make, and why a capsule of retatrutide powder almost certainly isn't one.
Status as of October 21, 2026: retatrutide is not approved by any regulator in the world. Lilly plans to file it with the FDA in Q1 2027. The only FDA-approved GLP-1 pills for weight loss are the Wegovy pill (oral semaglutide) and Foundayo (orforglipron). Nothing below is medical or dosing advice.
Where I get mine: the vendors I use, and how I vetted them.
Is there an oral retatrutide?
No. I checked every route Lilly has registered, and none of them goes through your mouth.
ClinicalTrials.gov lists 33 studies of retatrutide (Lilly's code name for it is LY3437943). In every one of them, the drug is "Administered SC," meaning a subcutaneous injection. One early study also tested it by IV (ClinicalTrials.gov, searched Oct 21, 2026). The only pills in any of those studies are other drugs given alongside it, like birth control or caffeine, to check for interactions.
Lilly's July release on its latest phase 3 wins calls retatrutide "an investigational, once-weekly, triple hormone receptor agonist" and says nothing about an oral form. It says Lilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" (Lilly, July 23, 2026). A JAMA news piece this month describes the phase 3 program as "weekly injections of retatrutide" (JAMA, Oct 9, 2026).
So "retatrutide pills" isn't a product in development that's leaked early. It doesn't exist in the research at all. What retatrutide does exist legally, and where, is covered in can you legally get retatrutide.
What GLP-1 pills are approved for weight loss?
Two, both approved within the last year.
Wegovy pill (oral semaglutide). Novo Nordisk announced FDA approval on December 22, 2025, calling it "the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management" (Novo Nordisk, Dec 22, 2025). It's the same molecule as the Wegovy and Ozempic shots.
Foundayo (orforglipron). Lilly announced FDA approval on April 1, 2026, for adults with obesity or overweight with a weight-related medical problem (Lilly, April 1, 2026). Its label carries the same weight-management indication (Foundayo label, rev. 07/2026).
Rybelsus, the older semaglutide pill, gets lumped in a lot. Its label is for type 2 diabetes and heart risk in people with type 2 diabetes. It is not approved for weight loss (Rybelsus label, rev. 1/2026).
Here's how the options line up. Frequency only, straight from each label.
Drug | Form | Approved for weight loss? | How often, per label | Source |
|---|---|---|---|---|
Retatrutide | Injection under the skin (trials only) | No. Not approved anywhere | Once weekly in trials; no label exists | |
Wegovy pill (semaglutide) | Tablet | Yes | Once daily, empty stomach, wait 30 minutes | |
Foundayo (orforglipron) | Tablet | Yes | Once daily, with or without food | |
Wegovy injection (semaglutide) | Injection under the skin | Yes | Once weekly | |
Zepbound (tirzepatide) | Injection under the skin | Yes | Once weekly | |
Rybelsus (semaglutide) | Tablet | No. Type 2 diabetes only | Once daily, empty stomach | |
"Retatrutide pills/capsules" sold online | Capsule or tablet | No | None. No label, no trial | No source exists |
If you're weighing what the approved options cost against the gray market, I broke that down in how much retatrutide costs.
Why are most peptides injected instead of taken as pills?
Because your gut is built to destroy them. Swallow a peptide and stomach acid and digestive enzymes chop it up, and what survives barely crosses the gut wall.
That's not my phrasing. It's how Novo Nordisk's own scientists opened their paper on the semaglutide pill: "Oral administration of therapeutic peptides is hindered by poor absorption across the gastrointestinal barrier and extensive degradation by proteolytic enzymes" (Sci Transl Med, 2018).
Novo's workaround was an absorption enhancer called SNAC (salcaprozate sodium), pressed into the tablet with the semaglutide. Per the same paper, SNAC shields the drug from enzymes by buffering the spot right around the tablet, and the drug is absorbed in the stomach, close to the tablet's surface. That's why the label tells you to take it on an empty stomach with only a little water and then wait before eating.
Even with all that engineering, very little gets in. The Wegovy label puts the absolute bioavailability of the tablet at "approximately 1% to 2%" (Wegovy label, rev. 06/2026). The Rybelsus label says 0.4% to 1% (Rybelsus label). That's why the pill contains far more semaglutide per day than the weekly shot delivers. The Wegovy label also notes blood levels from the pill vary more from person to person than from the injection.
Foundayo gets around the problem a different way: it isn't a peptide. Lilly calls it "a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist" (Lilly, April 1, 2026). Its label reports 77% absolute bioavailability at the starting dose (Foundayo label). It's a regular pill-shaped drug that happens to hit the same receptor.
Pill | What it is | How much reaches the blood (per label) |
|---|---|---|
Wegovy pill | Peptide plus SNAC absorption enhancer | About 1% to 2% |
Rybelsus | Peptide plus SNAC absorption enhancer | About 0.4% to 1% |
Foundayo | Small molecule, not a peptide | 77% at the starting dose |
What are the "retatrutide pills" sold online?
Unverified products. Nobody has published what's in them, and no trial has tested retatrutide by mouth.
Retatrutide is a peptide, like semaglutide. Getting even 1% of semaglutide through the gut took Novo a dedicated absorption enhancer and years of work, and its own researchers found the absorption mechanism was "compound specific" (Sci Transl Med, 2018). That means you can't assume a capsule of retatrutide powder gets absorbed at all. Nobody has shown that it does, and I couldn't find anyone who has even tried to measure it.
Then there's the question of whether it's retatrutide. The FDA warns that illegally marketed versions of these drugs "could contain the wrong ingredients or harmful ingredients," and that it has warned companies selling retatrutide and other GLP-1s "falsely labeled 'for research purposes' or 'not for human consumption'" (FDA, content current as of Oct 1, 2026). That FDA page talks about injectables. It doesn't mention pills at all.
The testing that has been done on products labeled retatrutide isn't reassuring. Per JAMA, University of Queensland researchers tested three products labeled retatrutide and found they "did contain it, but not the amount specified," with one holding about half what the label claimed. Australia's regulator tested another after a serious adverse event and found it "contained a high dose of semaglutide and no retatrutide" (JAMA, Oct 9, 2026). Those were injectable products. A capsule adds the absorption problem on top of the identity problem.
If you're thinking about moving off something you're already on, I went through what the trials did and didn't test in switching from tirzepatide to retatrutide.
Is oral BPC-157 as good as injected?
Nobody knows, because almost nobody has tested BPC-157 in people by any route. The oral studies are in rats.
The best single summary is FDA's own briefing document for its July advisory committee meeting (FDA, July 23-24, 2026). Here's what it says, route by route:
Animal studies used oral dosing. Several rat studies FDA reviewed gave BPC-157 "orally (via drinking water)" or by injection into the abdomen. None of that tells you what happens in a person.
The one oral human trial never reported. A phase 1 trial of BPC-157 tablets in healthy people in Mexico was registered in 2015. FDA says "There are no results posted, and we were unable to find an associated published study." Its registry status is "Unknown" (ClinicalTrials.gov, NCT02637284).
The human studies that do exist used other routes. FDA found five small clinical studies: rectal enemas, injections into the knee, injections into the bladder, and an IV infusion in two healthy people. FDA wrote that it "found no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal" routes.
Nobody knows how much gets absorbed. FDA notes the absolute bioavailability of BPC-157 by mouth, under the skin or in the nose is unknown even in rats and dogs, and that "There is no information to assess the pharmacokinetics of BPC-157 in humans."
FDA also notes BPC-157 "is marketed in the United States as an ingredient in dietary supplement products formulated as oral capsules and tablets." Being on a shelf as a capsule doesn't mean anyone measured whether the capsule works. Where BPC-157 stands with the FDA now is on the compounding status tracker, and what it costs by route is in how much BPC-157 costs.
So, pill or injection?
If you want a pill that's been tested for weight loss, there are exactly two, and you get them with a prescription. If you want retatrutide, it's an injection, and today it only exists legally in Lilly's trials and its expanded access program.
A "retatrutide pill" is the worst of both worlds: an unapproved drug in a form nobody has shown can get into your blood.
Before you start anything: get a baseline blood panel. I use Superpower for mine. It's on my vendors and tools page, along with the vendors I use (code BHN40 for 40% off).
Reply and tell me: have you seen "retatrutide capsules" or "oral retatrutide" pitched to you, and where? An ad, a Reddit DM, a telehealth site? Don't send me names. Tell me the shape of the pitch and what it promised. If enough of you write in, I'll publish what this corner of the market looks like.